Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives

Objective: Endothelial function is of prognostic importance for hypertensives. The aim of this study was to investigate the effects of irbesartan combined with diltiazem on the endothelium-dependent vasodilatation in essential hypertensive (EH) patients in China. Methods: A total of 150 Chinese hype...

Full description

Bibliographic Details
Main Authors: Tingting Zhou, Xiaodong Huang, Xiaoqi Cai, Liangdi Xie
Format: Article
Language:English
Published: Taylor & Francis Group 2017-10-01
Series:Clinical and Experimental Hypertension
Subjects:
Online Access:http://dx.doi.org/10.1080/10641963.2017.1306537
_version_ 1797681524203585536
author Tingting Zhou
Xiaodong Huang
Xiaoqi Cai
Liangdi Xie
author_facet Tingting Zhou
Xiaodong Huang
Xiaoqi Cai
Liangdi Xie
author_sort Tingting Zhou
collection DOAJ
description Objective: Endothelial function is of prognostic importance for hypertensives. The aim of this study was to investigate the effects of irbesartan combined with diltiazem on the endothelium-dependent vasodilatation in essential hypertensive (EH) patients in China. Methods: A total of 150 Chinese hypertensives aged from 40 to 80 years old were assigned into three groups: irbesartan treated(150 mg/d, n = 46), diltiazem treated (90 mg/d, n = 51), and combined therapy group (irbesartan 150 mg/d+ diltiazem 90 mg/d, n = 53). Forty age and gender-matched normotensives without clinical manifestation of cardiovascular diseases served as controls. High-resolution ultrasonography was used to assess flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation (NMD) in the brachial artery. Left ventricular mass index (LVMI) was calculated. Fibrinogen (Fg) was determined by Clauss and Stago auto analyzer. Blood pressure was measured using mercury sphygmomanometers. Results: FMD and NMD were lower in combined treatment group compared to normotensives before treatment at baseline [FMD(8.39 ± 3.04)% vs. (11.21 ± 3.88)%, NMD (13.96 ± 5.71)% vs. (16.78 ± 6.22)%, p < 0.05]. FMD was improved significantly after the combined therapy [(10.72 ± 3.46)% vs. (8.39 ± 3.04)%, p < 0.05]. No significant difference in NMD was found among three hypertensive groups after therapy. Moreover, FMD increased significantly with the prolongation of treatment. After stratification of age, FMD in younger EH patients under 65 years old was markedly increased after treatment within 1 year, whereas FMD in EH patients over 65 years old showed a significant increase after 3-year therapy. In addition, LVMI was reduced in hypertensives after combined therapy [(99.1 ± 17.9) g/m2 vs. (90.6 ± 16.2) g/m2, p < 0.01]. Logistic analysis showed that age was an important risk factor for FMD. Conclusions: Combined therapy of irbesartan with diltiazem ameliorated endothelial function.
first_indexed 2024-03-11T23:46:04Z
format Article
id doaj.art-7f2f51d854254fc3a406e790737b95c0
institution Directory Open Access Journal
issn 1064-1963
1525-6006
language English
last_indexed 2024-03-11T23:46:04Z
publishDate 2017-10-01
publisher Taylor & Francis Group
record_format Article
series Clinical and Experimental Hypertension
spelling doaj.art-7f2f51d854254fc3a406e790737b95c02023-09-19T09:24:46ZengTaylor & Francis GroupClinical and Experimental Hypertension1064-19631525-60062017-10-0139761261810.1080/10641963.2017.13065371306537Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensivesTingting Zhou0Xiaodong Huang1Xiaoqi Cai2Liangdi Xie3Fujian Medical University, Fujian Hypertension Research InstituteFujian Hypertension Research Institute, First Affiliated Hospital of Fujian Medical UniversityFujian Hypertension Research Institute, First Affiliated Hospital of Fujian Medical UniversityFujian Hypertension Research Institute, First Affiliated Hospital of Fujian Medical UniversityObjective: Endothelial function is of prognostic importance for hypertensives. The aim of this study was to investigate the effects of irbesartan combined with diltiazem on the endothelium-dependent vasodilatation in essential hypertensive (EH) patients in China. Methods: A total of 150 Chinese hypertensives aged from 40 to 80 years old were assigned into three groups: irbesartan treated(150 mg/d, n = 46), diltiazem treated (90 mg/d, n = 51), and combined therapy group (irbesartan 150 mg/d+ diltiazem 90 mg/d, n = 53). Forty age and gender-matched normotensives without clinical manifestation of cardiovascular diseases served as controls. High-resolution ultrasonography was used to assess flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation (NMD) in the brachial artery. Left ventricular mass index (LVMI) was calculated. Fibrinogen (Fg) was determined by Clauss and Stago auto analyzer. Blood pressure was measured using mercury sphygmomanometers. Results: FMD and NMD were lower in combined treatment group compared to normotensives before treatment at baseline [FMD(8.39 ± 3.04)% vs. (11.21 ± 3.88)%, NMD (13.96 ± 5.71)% vs. (16.78 ± 6.22)%, p < 0.05]. FMD was improved significantly after the combined therapy [(10.72 ± 3.46)% vs. (8.39 ± 3.04)%, p < 0.05]. No significant difference in NMD was found among three hypertensive groups after therapy. Moreover, FMD increased significantly with the prolongation of treatment. After stratification of age, FMD in younger EH patients under 65 years old was markedly increased after treatment within 1 year, whereas FMD in EH patients over 65 years old showed a significant increase after 3-year therapy. In addition, LVMI was reduced in hypertensives after combined therapy [(99.1 ± 17.9) g/m2 vs. (90.6 ± 16.2) g/m2, p < 0.01]. Logistic analysis showed that age was an important risk factor for FMD. Conclusions: Combined therapy of irbesartan with diltiazem ameliorated endothelial function.http://dx.doi.org/10.1080/10641963.2017.1306537diltiazemendothelial functionendothelium-dependent vasodilatationhypertensionirbesartan
spellingShingle Tingting Zhou
Xiaodong Huang
Xiaoqi Cai
Liangdi Xie
Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
Clinical and Experimental Hypertension
diltiazem
endothelial function
endothelium-dependent vasodilatation
hypertension
irbesartan
title Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
title_full Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
title_fullStr Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
title_full_unstemmed Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
title_short Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
title_sort combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
topic diltiazem
endothelial function
endothelium-dependent vasodilatation
hypertension
irbesartan
url http://dx.doi.org/10.1080/10641963.2017.1306537
work_keys_str_mv AT tingtingzhou combinedtreatmentofirbesartananddiltiazemamelioratesendotheliumdependentvasodilatationinhypertensives
AT xiaodonghuang combinedtreatmentofirbesartananddiltiazemamelioratesendotheliumdependentvasodilatationinhypertensives
AT xiaoqicai combinedtreatmentofirbesartananddiltiazemamelioratesendotheliumdependentvasodilatationinhypertensives
AT liangdixie combinedtreatmentofirbesartananddiltiazemamelioratesendotheliumdependentvasodilatationinhypertensives